INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

作者需在提交过程中列出每位作者的贡献，并在致谢部分之后包含作者贡献标题；提交时提供的信息将在校对阶段显示在作者贡献标题下。 模型中文摘要

You will be asked to list the contribution of each author as part of the submission process. Please include the Author Contributions heading within your submission after the Acknowledgements section. The information you give on submission will then show under the Author Contributions heading later at the proofing stage.

作为发表条件，作者须在相关公共数据存储库共享研究数据，并包含数据可用性声明，说明数据是否可用和共享，某些情况下说明数据可用但未共享及原因。 模型中文摘要

The Journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages. As a condition of publication authors are required to: Share your research data in a relevant public data repository Include a data availability statement. This sho…

作者需在稿件中包含伦理批准声明，即使方法部分已包含相关信息；若无需伦理批准，必须明确说明；涉及人类参与者、人类数据或人体组织的研究必须声明相关伦理委员会或机构审查委员会批准或豁免，并提供委员会全名、机构及批准号。 模型中文摘要

Please include your ethics approval statements under this heading, even if you have already included ethics approval information in your methods section. If ethical approval was not required, you need to explicitly state this. All papers reporting studies involving human participants, human data or human tissue must state that the relevant Ethics Committee or Institutional Review Board approved th…

该期刊为开放获取期刊，接受的文章在出版后立即免费在线发布，采用知识共享许可；稿件经同行评审被接受后需支付一次性文章处理费（APC）3200美元，由资助方、机构或作者支付，提交稿件不收费。 模型中文摘要

International Journal of Immunopathology and Pharmacology is an open access, peer-reviewed journal. All accepted articles are made freely available online immediately upon publication, are published under a Creative Commons license, and hosted online in perpetuity. If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable to cover the…

该期刊为单盲同行评审，审稿人与编辑互动，不公布审稿信息；稿件先经初步评估，不符合要求将被退回修改，不合适或超出范围的稿件可能未经同行评审即被拒稿。 模型中文摘要

The following summary describes the peer review process for this journal: Identity transparency: Single-anonymized Reviewer interacts with: Editor Review information published: None Your manuscript will undergo an initial evaluation. If it does not conform to the requirements laid out in these guidelines, it will be returned to you for amendments prior to peer review. Manuscripts may be desk rejec…

期刊和Sage非常重视版权侵权、抄袭或其他违反出版最佳实践的问题，请阅读Sage关于抄袭的完整政策及可能采取的措施。 模型中文摘要

The journal and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. Please read Sage's complete policy on plagiarism and the actions we may take.

期刊接受已在预印本服务器发布的稿件，提交时需在指定字段输入预印本DOI，并建议在提交时告知编辑部；同行评审期间不应在预印本服务器发布更新版本。 模型中文摘要

The journal will consider submissions of manuscripts that have been posted on preprint servers. Please enter the preprint DOI in the designated field when submitting your manuscript. We advise that you inform the Journal Editorial office about your posted preprint at submission. Note that you should not post an updated version of your manuscript on a preprint server while it is being peer reviewed…

期刊遵循ICMJE要求，临床试验须在首个受试者入组时或之前在WHO认可的公共试验注册机构注册，作为发表考虑的条件；试验注册库名称、URL和注册号必须包含在摘要末尾。 模型中文摘要

The journal conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first participant enrollment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.